Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

Rosenberg, J E; Halabi, S; Sanford, B L; Himelstein, A L; Atkins, J N; Hohl, R J; Millard, F; Bajorin, D F; Small, E J

Rosenberg, J E; Halabi, S; Sanford, B L; Himelstein, A L; Atkins, J N; Hohl, R J; Millard, F; Bajorin, D F; Small, E J.

Affiliation

Rosenberg JE; Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA. jrosenbe@medicine.ucsf.edu

Ann Oncol ; 19(5): 946-50, 2008 May.

Article in En | MEDLINE | ID: mdl-18272914

Subject(s)

Antineoplastic Agents/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Boronic Acids/therapeutic use; Carcinoma, Transitional Cell/drug therapy; Protease Inhibitors/therapeutic use; Pyrazines/therapeutic use; Salvage Therapy; Urologic Neoplasms/drug therapy; Aged; Antineoplastic Agents/adverse effects; Boronic Acids/adverse effects; Bortezomib; Carcinoma, Transitional Cell/mortality; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases/chemically induced; Hematologic Diseases/chemically induced; Humans; Male; Middle Aged; Protease Inhibitors/adverse effects; Pyrazines/adverse effects; Treatment Failure; Urologic Neoplasms/mortality

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protease Inhibitors / Pyrazines / Boronic Acids / Carcinoma, Transitional Cell / Antineoplastic Combined Chemotherapy Protocols / Urologic Neoplasms / Salvage Therapy / Antineoplastic Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2008 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google